ImageneBio reported a net loss of $10.2 million, or $0.63 per share, for the quarter ended June 30, 2026, compared to a $10.7 million loss in the prior year period. Research and development expenses increased to $6.7 million from $5.7 million, while general and administrative expenses rose to $5.1 million from $1.7 million due to personnel-related costs. The company held $136.2 million in cash and marketable securities as of June 30, 2026, providing funding through the first quarter of 2028. Clinical updates include continued enrollment in the Phase 2b ADAPTIVE trial for atopic dermatitis and plans to initiate a Phase 2 study for alopecia areata in 2026. The company also appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel, while Dr. Ben Porter-Brown transitioned to a consulting role. ImageneBio is a clinical-stage biotechnology company developing therapeutics for immunological and autoimmune diseases.

ImageneBio, Inc. appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer, effective July 20, 2026. Grant-Huerta, formerly of Atara Biotherapeutics and Amgen Inc., will receive an annual base salary of $450,000, a 40% target annual bonus, 65,000 restricted stock units, and 95,000 stock options. Additionally, Chief Medical Officer Benjamin Porter-Brown will transition to a consulting role effective July 24, 2026. ImageneBio, Inc. is a biotechnology company.

Robert Lally, Senior Vice President of Finance and Operations and principal accounting officer, resigned on June 22, 2026, effective July 22, 2026. The company stated the resignation was not due to any disagreement and is searching for a replacement. ImageneBio, Inc. operates in the biotechnology industry, focusing on genetic medicine and therapeutics.